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Abstract
Background—Organ transplantation has seen an increased utilization of organs from older 
donors over the past decades in an attempt to meet the globally growing shortage of donor organs. 
However, inferior transplant outcomes when utilizing older donor organs represent a growing 
challenge. 
Methods and Results—Here, we characterize the impact of donor age on solid organ 
transplantation using a murine cardiac transplantation model. We found a compromised graft 
survival when utilizing older hearts. Shorter graft survival of older hearts was independent of 
organ age per se, as chimeric young or old organs repopulated with young passenger leukocytes 
showed comparable survival times. Transplantation of older organs triggered more potent 
alloimmune responses via intragraft CD11c+ dendritic cells (DCs) augmenting CD4+ and CD8+ T 
cell proliferation and pro-inflammatory cytokine production, particularly that of IL-17A. Of note, 
depletion of donor CD11c+ DCs prior to engraftment, neutralization of IL-17A or transplantation 
of older hearts into IL-17A-/- mice delayed rejection and reduced alloimmune responses to levels 
observed when transplanting young hearts. 
Conclusions—These results demonstrate a critical role of old donor CD11c+ DCs in mounting 
age-dependent alloimmune responses with an augmented IL-17A response in recipient animals. 
Targeting IL-17A may serve as a novel therapeutic approach when transplanting older organs. 
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Introduction 
With the success of organ transplantation, age limits have essentially been lifted. Older organs 
have been increasingly utilized to compensate the increasing organ shortage 1. Organ age on the 
other hand has been linked to intrinsic chronic interstitial inflammation in general referred to as 
inflamm-aging, with reduced clearance of self- as well as exogenous antigens as hallmark 
findings 2. Moreover, older donor organs have not only shown greater fragility and increased 
susceptibility to injury, but have also elicited more potent systemic recipient immune responses 
through augmented immunogenicity. At the same time, mechanistic links between organ age and 
alloimmune responses remain unclear. 
Consistent with previous reports, we have previously shown in a large-scale clinical 
analysis that rates of acute rejection increase in parallel to donor age regardless of recipient age 3. 
It is well established that aging is associated with significant and broad changes of the immune 
system 4,5. The impact of these changes on transplant outcome, however, remains poorly 
understood. 
Increasing evidence indicates that there is an age-associated dysregulation in Th1 and 
Th2 cytokine synthesis 6. While the IL-2 signaling machinery has been shown to be critical for 
Th1 differentiation and proliferation, IL-2 has been established as an inhibitor of Th17 
development 7. Of significance for studies on immunosenescence and alloimmune responses, 
CD4+ T cells isolated from splenocytes of old mice produced higher amounts of IL-17 8. 
Using a fully allogenic heart transplant mouse model, we demonstrate that old cardiac 
allografts were rejected more rapidly, consistent with our clinical observations. Our data indicate 
that older CD11c+ dendritic cells (DCs) were the primary instigators of augmented alloimmune 
responses via IL-17A. Collectively, our data demonstrate that older organs skew the recipient 
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immune response towards CD4+IL-17A+ T cells via resident cardiac allograft CD11c+ cells in an 
age-dependent manner. At the same time, blocking IL-17A prolonged survival of older organs, 
thus revealing novel therapeutic opportunities.  
Methods
Study approval 
Animal use and care were in accordance with National Institutes of Health and Institutional 
Animal Care and Use Committee guidelines.
Animals 
8-12 week old wild type (WT) male C57BL/6 or DBA/2J WT male mice were purchased from 
Charles River Laboratories (Wilmington, MA). 18 month old WT male C57BL/6 mice were 
purchased from the National Institute of Aging (NIA, Bethesda, MD). 8-12 week old BALB/c 
IL-17-/- mice were bred at the Harvard School of Public Health Animal Facility; breeder pairs 
were kindly provided by Yoichiro Iwakura, Center for Experimental Medicine, Institute of 
Medical Science, University of Tokyo, Tokyo, Japan. 
Heterotopic heart transplantation  
Using a modified cuff technique, fully vascularized cardiac grafts from either old or young B6 
donor mice were heterotopically transplanted into young DBA/2J, young BALB/c WT or 
BALB/c IL-17-/- recipients, respectively. Hearts were anastomosed to recipient’s common carotid 
artery and internal jugular vein. Transplantation into the recipient’s cervical region facilitated 
reliable functional assessment through palpation. Ischemic times were kept consistently at 40 
min with an anastomosis time of 12 min. Graft function was measured daily by palpation, and 
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allograft rejection was defined as the complete cessation of palpable contractility. Graft survival 
is shown as the median survival time (MST) in days.  
In vivo treatment protocols 
For the generation of chimeric donors, young and old prospective cardiac donor C57BL/6 mice 
were lethally irradiated (11 Gy), eliminating all passenger leukocytes within the heart. Bone 
marrow was procured from young syngeneic C57BL/6 mice and transfused intravenously 24 
hours after irradiation (10u106 cells/animal). Mice were then used as cardiac allograft donors 
after six weeks, when cardiac tissue had been repopulated with leukocytes derived from the 
transplanted bone marrow. Successful repopulation was validated by immunohistochemistry. 
For the depletion of DCs, young and old cardiac donor C57BL/6 mice were treated 
intravenously with 0.5mg liposomal clodronate (Encapsula NanoSciences, Nashville, TN) at day 
8, 5 and 1 prior to graft procurement. This regimen insured depletion of intragraft CD11c+ 
dendritic cells as documented by flow cytometry analysis. 
For blockage of IL-17A, 100ȝg of anti-IL-17A (R&D systems, Minneapolis, USA) were 
administered intravenously to the recipient animals every other day following cardiac 
transplantation starting at day 0 until the day of complete rejection; the control group for this 
experiment was injected with isotype control antibodies using the same protocol.  
ELISpot Assay, ELISA 
ELISpot assays were performed using mouse IFNJ or mouse IL-6 ELISpot Kits (BD Biosciences, 
San Diego, CA), respectively. Briefly, 0.5u106 unselected splenocytes from DBA/2J recipients 
were used as responder cells and restimulated with 0.5u106 irradiated splenocytes from naïve 
donor-type B6 animals within 96 well ELISpot plates for 24 hours under standard cell culture 
conditions (using RPMI 1640 medium supplemented with 10% FCS, 1% penicillin/streptomycin 
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and 1% L-glutamine; 37qC; 5% CO2). Alternatively, 1u106 splenocytes from naïve DBA/2J mice 
used as responder cells to 104 flow-sorted splenic CD11c+ DCs (untreated or stimulated for 24 
hours with 100 ng/ml lipopolysaccharide, LPS) isolated from either young or old naïve B6 mice. 
The ELISpot assay was adapted to measure the frequency of alloreactive T cells producing IFNJ 
or IL-6, respectively. The resulting spots were counted on a computer-assisted enzyme-linked 
immunospot image analyzer (Cellular Technology), and frequencies were expressed as numbers 
of cytokine-producing spots per 0.5u106 or 1u106 responder cells. 
For detection of IL-17A in vitro, ELISA was performed. Mouse IL-17A was measured 
using commercial kits (eBioscience). Briefly, ELISA plates were coated with 100ȝl of anti-
cytokine capture antibody at 4°C overnight. Plates were then washed 5x with 0.05% PBS-Tween 
(PBST) and coated for 1 hour with the blocking buffer provided by the manufacturer. Samples or 
standards were added in duplicates (100μl/well) and incubated at 4°C overnight. Wells were 
washed 5x with PBST and incubated with 100μl of anti-cytokine detection antibody at 4°C 
overnight. Wells were then washed 5x with PBST and incubated with 100μl of avidin-HRP at 
room temperature for 30 minutes. Thereafter, wells were washed 7x with PBST and incubated 
with 100μl/well of a substrate. The reaction was stopped after 15min with 1M H2SO4 and 
absorbance was measured using a multiplate microplate fluorescence reader (Synergy HT, 
Biotek, Winooski, VT) at 405nm.
Cell isolation 
Single-cell leukocyte suspensions were obtained from spleens of young (8-12 weeks) DBA/2J 
WT mice by negative selection using anti-mouse antibodies against CD8, CD11b, CD11c, CD19, 
CD24, CD25, CD44, CD45R, CD49b, TCRȖ/į and TER119 using the EasySep™ Mouse Naïve 
CD4+ T Cell Isolation Kit (Stemcell Technologies, Vancouver, British Columbia, Canada) 
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according to manufacturer’s protocol. For isolation of CD11c+ DCs, single cell suspensions were 
obtained from hearts of young (8-12 weeks) and old (18 months) C57BL/6 WT mice. Briefly, 
hearts were procured and washed x3 with Ca2+- and Mg2+-free PBS. Tissue was then cut into 5 
mm pieces and placed in tissue extraction buffer (5mM EDTA, 2mM 2-ME in PBS), and 
incubated with continuous, brisk stirring at 37°C for 30 minutes; suspension was then filtrated 
through a 70ȝm filter. CD11c+ DCs were then isolated using EasySep™ Mouse CD11c Positive 
Selection Kit (Stemcell Technologies) according to the manufacturer’s protocol. 
Statistical analysis 
Kaplan-Meier survival graphs were constructed and log-rank comparisons of groups were used 
to calculate P values. Student’s t-test was used for comparison of means between two groups. No 
multiple testing correction was performed. A P value <0.05 was considered as statistically 
significant. Data were expressed as mean ± standard error of the mean (SEM). GraphPad Prism 
version 6, GraphPad Software, La Jolla, CA, USA, was used for statistical analysis. 
Additional methods are detailed in the online Supplemental Material. 
Results
Cardiac allografts from old donors are rejected more rapidly 
We have previously shown in a large-scale clinical study that episodes of acute rejection were 
more frequent when utilizing older organs for transplantation 3. To shed light on this clinical 
observation and to understand underlying mechanisms, we transplanted fully MHC-mismatched 
cardiac allografts from either young (10-12 weeks) or old (18 months) C57BL/6 donor mice into 
young DBA/2J recipients. In this heterotopic and fully vascularized cardiac transplant model, old 
hearts showed a significantly shorter graft survival (Fig. 1a). Furthermore, old cardiac allografts 
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displayed more advanced ISHLT rejection scores compared to allografts procured from young 
donors (Fig. 1b). Moreover, intragraft immunohistological analysis demonstrated increased 
CD4+ and CD8+ T cell infiltrates (Fig. 1c). Collectively, these findings documented age-
dependent differences in cardiac allograft survival correlating with increased lymphocellular 
infiltration and advanced structural changes. 
Accelerated rejection of cardiac allografts from old donors is associated with an enhanced 
systemic alloimmune response 
To determine donor age-related effects on systemic alloimmune responses within recipients, 
frequencies of splenic CD4+/CD8+ effector T cells and CD4+ regulatory T cells (Tregs) were 
assessed by day 7 after transplantation. While frequencies of CD4+CD25+FoxP3+ Tregs were 
age-independent, recipients of cardiac allografts from old donors showed significantly increased 
frequencies of CD8+CD44highCD62low and higher rates of CD4+CD44highCD62low effector T cells 
(Supplemental Fig. 1a). Importantly, transplantation of old cardiac allografts also led to 
elevated frequencies of CD8+IFNJ+ T cells among recipient splenocytes as assessed by 
intracellular cytokine staining (Supplemental Fig. 1b).  
Properties of recipient splenocytes were further characterized in vitro by restimulation 
with donor-type antigen and subsequent measurements of cytokine production and proliferative 
responses. ELISpot data indicated increased frequencies of responder T cells that produced IFNJ 
and IL-6 upon donor- antigen stimulation (Supplemental Fig. 1c). Moreover, an increased 
proliferation of alloreactive splenocytes responding to donor-type antigen was noted 
(Supplemental Fig. 1d). Taken together, these results indicated that older cardiac allografts 
enhanced systemic alloimmune responses of recipient mice. 
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Passenger leucocytes mediate donor age-dependent transplant survival and alloimmune 
responses
Passenger leukocytes have been shown to play an important role in allograft rejection 9-11. The 
age of passenger leukocytes has previously been shown to impact allograft rejection 12-14. 
However, age-related changes in parenchymal tissue may also be of relevance in allograft 
rejection 15-17. Thus, to delineate whether the observed effects of donor age on allograft survival 
and systemic alloimmune responses were linked to age-dependent changes in parenchymal tissue 
or mediated by age-dependent modifications of passenger leukocytes residing within the graft, 
we generated chimeric C57BL/6 donor animals through lethal total body irradiation and 
subsequent hematopoietic reconstitution with bone marrow procured from young naïve 
syngeneic C57BL/6 mice. By 6 weeks, young or old hearts from chimeric animals where 
transplanted into young WT DBA/2J animals. To validate this chimeric model, CD11c+ staining 
was performed 6 weeks after repopulation (Fig. 2a). 
When chimeric old or young hearts repopulated with young passenger leukocytes had 
been transplanted into young DBA/2J mice, graft survival was no longer donor age-dependent 
(Fig. 2b). Similarly, histomorphological changes, as assessed by ISHLT rejection scores at day 7, 
were no longer age-dependent (Fig. 2c). Moreover, systemic immune responses following the 
engraftment of chimeric grafts demonstrated comparable frequencies of CD4+ and CD8+ effector 
T cells (Supplemental Fig. 2a). No significant difference was observed in frequencies of 
CD4+CD25+FoxP3+ cells (Supplemental Fig. 2a). In addition, following re-stimulation of 
recipient responder splenocytes with donor-type antigen, frequencies of IFNJ-producing 
alloreactive splenocytes did not differ in recipients of either old or young chimeric hearts 
(Supplemental Fig. 2b). Of note, there was a significant decrease in frequencies of IL-6 
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producing alloreactive splenocytes in recipients of old chimeric hearts (Supplemental Fig. 2b). 
Moreover, proliferation rates of recipient-derived splenocytes following transplantation of 
chimeric hearts were independent of organ age (Supplemental Fig. 2c).  
Collectively, these results suggest that the impact of donor age on alloimmune responses 
is not related to the age of cardiac parenchyma but rather to the age of passenger leukocytes. 
CD11c+ dendritic cells mediate donor age-related effects of augmented alloimmune 
responses 
Due to their ability to migrate to secondary lymphoid tissues and to present alloantigens, donor 
DCs are considered instigators of adaptive alloimmune responses 10,11,18. Thus, to determine 
whether CD11c+ DCs play a role in mediating the observed augmented alloimmune response 
when transplanting older organs, donor DCs were depleted by liposomal clodronate prior to 
transplantation. Consistent with previous studies 19,20, liposomal clodronate pretreatment resulted 
in a dramatic depletion (>98%) of CD11c+ DCs in donor hearts (Fig. 3a). Of note, pretreatment 
with liposomal clodronate had only minor effects on macrophage populations residing within 
cardiac tissue (Fig. 3a). Next, CD11c+ DC-depleted donor cardiac allografts were transplanted 
into young recipients and survival was assessed. Depletion of CD11c+ DCs prolonged survival of 
old cardiac allografts to levels comparable to that observed when young allografts had been 
transplanted (Fig. 3b). Moreover, ISHLT rejection scores were comparable in both, young and 
old cardiac allografts subsequent to clodronate treatment (Fig. 3c). In addition, systemic 
alloimmune responses were age-independent following donor treatment with clodronate as 
assessed by splenic T cell populations (Supplemental Fig. 3a), intracellular cytokine staining 
(Supplemental Fig. 3b), frequencies of IFNȖ and IL-6 producing alloreactive splenocytes 
(Supplemental Fig. 3c), and proliferation of alloreactive splenocytes (Supplemental Fig. 3d). 
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Taken together, these findings suggest that intragraft CD11c+ DCs are the primary mediators of 
age-dependent immune responses and accelerated allograft rejection observed when 
transplanting old cardiac allografts. 
Aged CD11c+ dendritic cells demonstrate increased allostimulatory capacities in vitro 
To investigate mechanisms of donor DC-mediated effects on alloimmunity in detail and to 
delineate the impact of immunosenescence on DCs, flow-sorted naïve splenic CD11c+ DCs were 
characterized. Both naïve and LPS-stimulated CD11c+ DCs isolated from old C57BL/6 mice 
used as allogeneic stimulators to splenocytes from young naïve DBA/2J mice evoked 
significantly stronger alloimmune responses with elevated frequencies of IFNȖ-producing 
responder cells (Fig. 4a) in addition to increased proliferation rates (Fig. 4b). Pre-activation with 
LPS increased the overall allostimulatory level of both young and old DCs in a dose-dependent 
manner. Moreover, flow cytometry revealed a significant increase in surface expression of 
activation and maturation markers including I-Ab (MHC-II), CD40, CD80, and CD86 on old 
DCs (Fig. 4c), supporting the concept of intrinsic functional modifications in older DCs. 
IL-17A is critical in enhancing the rejection of older allografts 
Elevated frequencies of Th17 cells have been observed in old mice and humans 21,22. More 
importantly, Th17 cells have been linked to critical pathways in allograft rejection 23. To dissect 
the role of Th17 cells in this process in more detail, we explored whether elevated levels of 
intragraft IL-17A were immanent to organ age per se or linked to age-dependent alloimmune 
responses elicited by old passenger leukocytes residing within the graft. 
Cardiac allografts were collected prior to rejection (day 7) and IL-17A mRNA levels were 
quantified by real-time PCR. Results indicated a dramatic increase in IL-17A mRNA levels in 
old cardiac allografts (> 30-fold increase, Fig. 5a). Of note, old and young cardiac allografts 
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showed equally low levels of IL-17A mRNA following the engraftment of organs that were pre-
treated with liposomal clodronate (Fig. 5a). Next, isolated DCs of hearts from old (18 months) or 
young (8-12 weeks) C57BL/6 mice were co-cultured with isolated naïve CD4+ cells (ratio 1:5) 
for 7 days in media alone, under Th17 polarizing conditions alone, in LPS alone or under Th17 
polarizing conditions in the presence of LPS. LPS-activated DCs from older cardiac allografts in 
Th17-polarizing conditions increased frequencies of CD4+IL-17A+ T cells dramatically (49.3% 
vs. 24.2% in DCs from younger hearts; P<0.0001, Fig. 5b). Of note, neither old or young DCs in 
media alone, Th17 polarizing conditions alone or in the presence of LPS alone demonstrated 
significant differences in the proliferation of CD4+IL-17A+ T cells, suggesting that both, 
activation of donor DCs and Th17 polarizing conditions are required during the rejection of older 
allografts. These results were confirmed by ELISA (Fig. 5c). Taken together, these findings 
suggest a prominent role for IL-17A in mounting an augmented immune response linked to the 
engraftment of older donor organs. 
Blocking IL-17 in recipient animals prolongs the survival of old but not young cardiac 
allografts
Our results thus far suggested a critical role of IL-17A in alloimmune responses subsequent to 
the transplantation of older grafts. To evaluate the role of IL-17A in vivo, we first performed a 
functional blockade of IL-17A by treating recipients of young or old C57BL/6 allografts with 
anti-IL-17A starting at the day of transplantation. Survival of older allografts was significantly 
prolonged subsequent to the application of anti-IL-17A. Of note, anti-IL-17A treatment did not 
significantly prolong the survival of young allografts (Fig. 6a). 
To explore the critical role of IL-17A in vivo further, hearts of old and young donors were 
transplanted into IL-17-/- BALB/c mice. Indeed, the absence of IL-17 prolonged graft survival of 
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old hearts (MST 12 vs. 9 days in IL-17-/- mice compared to WT recipients; P<0.05, Fig. 6b), 
while survival of young cardiac allografts remained unaltered (WT vs. IL-17-/- mice recipients; 
MST 11.5 vs. 11 days; NS; Fig. 6c). 
These in vivo results emphasize the prominent role for IL-17A in donor age-dependent 
alloimmune responses.
Discussion
The growing discrepancy between demand and supply in organ transplantation has resulted in an 
increased utilization of organs from old donors 24,25. Over the last decade, more than half of all 
transplanted kidneys were procured from donors older than 50 years 26. At the same time, 
transplant outcomes of extended criteria donor organs were found to be inferior to those 
observed in organs from younger donors 12. In cardiac transplantation, donations have dropped 
dramatically since 2000. While significantly more older recipients are receiving cardiac 
transplants, the age of heart donors is in general lower compared to the age of other solid organ 
transplant donors 27. Nevertheless, understanding age-specific aspects of immunogenicity and 
repair may provide desperately needed novel resources for cardiac transplantation. In a large 
retrospective analysis, we have recently shown that the transplantation of older organs is linked 
to more frequent rates of acute rejection 3. Despite vast clinical implications, experimental 
studies dissecting the effects of donor age on allograft immunogenicity and recipient immune 
responses remain scarce 28. Thus, dissecting mechanistic aspects of donor age-related immune 
responses appears of major clinical relevance. 
Our experimental data reflect clinical observations showing that older organs are rejected 
earlier. Albeit small, the difference in graft survival of 2 days had been highly significant. We 
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wish to point out that we used a cardiac transplant model with a fully MHC-mismatched donor-
/recipient combination leading to graft dysfunction subsequent to acute rejection in less than 2 
weeks. Moreover, aspects of age-dependent injury/repair, functional reserve or mismatching in 
donor/recipient size are likely to be superseded by the vigorous alloimmune response in this 
model. 
Furthermore, using a chimeric mouse model, we demonstrated that age-dependent 
alloimmune responses were not linked to the age of cardiac parenchyma. This model of complete 
depletion of intragraft leukocytes through lethal total-body irradiation and subsequent 
reconstitution with leukocytes derived from transplanted bone marrow has been established and 
used extensively by other investigators in the analysis of repopulation and residual APCs using 
flow cytometry and RT-PCR 29,30. For this work, repopulation of prospective allografts was 
confirmed by immunohistochemical staining (Fig. 2a). 
Impaired graft function correlated with organ age is most likely related to both, limited 
functional reserve and augmented immunogenicity. Physiological changes related to aging have 
been put forward as non-immunological factors influencing graft survival. In theory, increased 
susceptibility to tissue damage during the transplantation procedure subsequent to ischemia in 
addition to impaired repair mechanisms may be linked to a pro-inflammatory milieu including 
increased DAMP signaling, eliciting and perpetuating secondary allospecific immune responses. 
While physiological aspects of aging may, at least in theory, impact organ function following 
transplantation, our results suggest that the age of cardiac parenchyma per se did not mediate 
donor age-dependent differences of alloimmunity, as old donor hearts containing young 
passenger leukocytes did not augment alloimmune responses. 
Previous publications have illustrated the central role of IFNȖ as well as CD4+ and CD8+ 
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cells in allograft rejection 23,31,32. In these studies, a feedback loop leading to the production of 
IL-2 by Th1 cells after allogenic stimulation has been characterized. Those events promote 
alloreactive cytotoxic CD8+ cells, which in turn produce IFNȖ, enhancing Th1 responses even 
further. Our data confirm these findings by showing increased frequencies of CD4+IFNȖ+ and 
CD8+IFNȖ+ effector cells subsequent to the engraftment of both, young and old cardiac allografts. 
Of note, we observed higher frequencies of CD8+IFNȖ+ T cells when old allografts were 
transplanted. 
Recent clinical and experimental studies have shown the relevance of a novel CD4+ T 
helper population coined Th17 as instigators of allograft rejections. Th17 cells have been 
characterized by their signature cytokine IL-17A, a potent pro-inflammatory cytokine 33-35. Of 
note, studies outside of transplantation have shown that aging is associated with a general 
increase in levels of Th17 cells 36-38. However, the role of Th17 responses with respect to organ 
age remains unclear. Our results show a significant increase of intragraft IL-17A mRNA levels 
in old transplanted allografts. These results suggest a strong relationship between IFNȖ-
producing CD4+ and CD8+ as well as IL-17A-producing CD4+ cells in accelerating the rejection 
of older organs. To characterize the functional relevance and the origin of the highly elevated IL-
17A levels in older allografts in more detail, we co-cultured intragraft DCs of old and young 
C57BL/6 mice with splenic naïve CD4+ cells. Those experiments allowed us to distinguish 
whether elevated IL-17 levels were intrinsically related to aging or linked to the encounter with 
old passenger DCs. Our data demonstrated a significant increase of CD4+IL-17A+ cells after DC-
activation in Th17-polarizing conditions, thus confirming that old passenger DCs trigger a more 
potent IL-17A response. The role of IL-17A in allograft rejection was subsequently tested in
recipient animals deficient in IL-17A or those that were pretreated with anti-IL-17A. Both 
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recipients showed not only an improved allograft survival compared to untreated controls but 
also a prolonged survival of older compared to younger allografts, thus demonstrating the critical 
role of IL-17A in the rejection of older grafts. Taken together, these results underscore a novel 
and clinical relevant role of IL-17A in the rejection of older allografts. 
It is recognized that donor-derived APCs residing in the interstitium of allografts, in 
particular macrophages and DCs, are instigators of primary allospecific immune responses via 
direct alloantigen presentation to recipient responder cells within secondary lymphatic tissue 
11,14,39. However, due to their potent ability to instigate an adaptive immune response by 
activating naïve T cells, DCs are generally regarded as primary initiators of allograft rejection 
39,40. Both, clinical and experimental studies have shown that old APCs elicit enhanced 
alloimmune responses. Moreover, APCs collected from healthy elderly individuals co-cultured 
with purified T cells have elicited enhanced T cell proliferation in both, syngeneic and allogeneic 
settings 41. However, these studies failed to characterize phenotypic and functional aspects 
driving this process. In our studies, we focused on the role of DCs and characterized phenotypic 
and functional aspects. Our functional assays demonstrated that old DCs increased the 
proliferation and production of IFNȖ in allogeneic responder cells (CD4+ and CD8+ cells). Of 
note, augmented IFNȖ production was also observed subsequent to a stimulation with LPS, 
suggesting age-dependent allostimulatory capacities of old DCs even following unspecific 
preactivation. Moreover, depletion of old CD11c+ DCs by liposomal clodronate treatment 
blocked the recipients' Th17 response and extended allograft survival, suggesting that DCs play a 
central role in this process. Furthermore, old CD11c+ DCs presented advanced activation and 
maturity as shown by increased expression of MHC-II, CD80, CD86, and CD40. These data are 
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in accordance with results by others, showing an increased immunogenicity of old DCs in 
experimental graft-versus-host-disease models 42. 
Administered in a liposomal formulation, clodronate is selectively taken up by phagocytic 
leukocytes, particularly dendritic cells and macrophages 43. Following intracellular disruption of 
the liposomes through lysosomal phospholipases, accumulating clodronate leads to selective 
apoptosis of target cells 44. The observed depletion of DCs in our model (Fig. 3a) may be related 
to decreased permeability of cardiac capillaries to liposomal clodronate 45,46. Thus, effects in our 
model targeted predominantly circulating phagocytic leukocytes. With the turnover of resident 
macrophage being much slower than that of DCs 47, we do not assume a sizable effect of 
clodronate on cardiac macrophage populations subsequent to 1 week of treatment. Although our 
detailed in vitro and in vivo analysis supported the critical role of old DCs as instigators of organ 
age-dependent alloimmune responses, we cannot entirely rule out that other APCs including 
macrophages have been playing a role in organ age-dependent immune responses. 
Although data originating from experimental models have inherent shortcomings and 
might not always imply biological or even clinical significance, this work explains mechanistic 
findings of a previous clinical observation. Our experimental data show that donor age impacts 
not only organ quality but also recipient alloimmune responses through passenger leukocytes 
independent of unspecific or procedure-related injuries. This observation is intriguing as 
therapeutically interventions may influence graft survival and overall transplant outcome. 
Furthermore, we were able to identify the critical role of the age of DCs rather than organ age 
per se as a driving force of organ age-dependent alloimmune responses. These findings may not 
only advance our overall understanding of allograft rejection, but can potentially also lead to new 
specific translational strategies in recipients of older cardiac transplants.
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Figure Legends: 
Figure 1. Old cardiac allografts are rejected more rapidly. a, Hearts from old and young 
C57BL/6 mice were transplanted into young DBA/2J mice and mean survival times (MST) were 
analyzed. (n=7/group; **P<0.01; data are representative of two independent sets of experiments). 
b, 7 days after transplantation, mice were euthanized and transplanted hearts were procured; 
H&E staining was performed to asses lymphocytic infiltration and structural changes; samples 
were scored based on the International Society for Heart and Lung Transplantation (ISHLT) 
rejection score (n=8/group, magnification, 10x; *P<0.05). c, Paraffin sections were stained for 
CD4/CD8 to assess lymphocytic infiltration; data is shown as cells per high-power field (HPF) 
(n=8/group; *P<0.05; data are representative of two independent sets of experiments).
Figure 2. Old cardiac allografts from chimeric animals showed survival and rejection scores 
comparable to young cardiac allografts. Young and old C57BL/6 mice were lethally irradiated 
(11 Gy), thus eliminating passenger leukocytes. 24 hours after irradiation, bone marrow from 
young syngeneic C57BL/6 mice was injected intravenously to reconstitute passenger leukocytes 
within donor hearts. a, immunostaining for CD11c was performed 6 weeks after bone marrow 
transplantation to confirm successful repopulation of prospective donor hearts with DCs 
(representative slides; 10x). b-c, Hearts from young and old chimeric animals were transplanted 
into young WT DBA/2J mice; (b) mean survival time and (c) rejection scores by H&E staining 
were analyzed. (n=4/group; NS, non-significant; data are representative of two independent sets 
of experiments). 
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Figure 3. Clodronate depletion of DCs in older donors abolished previously observed 
accelerated rejection in younger recipients. Young and old C57BL/6 donors were treated 
intravenously with liposomal clodronate at -8, -5 and -1 days prior to graft procurement. a, This 
regimen insured depletion of intragraft CD11c+ DCs as documented by flow cytometry;, empty 
liposomes without clodronate were used as controls (n=3). b, DC-depleted hearts from young 
and old donors were transplanted into young DBA/2J mice and (b) mean survival time as well as 
(c) rejection scores as determined by H&E staining were analyzed. (n=5/group; NS, non 
significant; data are representative of two independent sets of experiments).
Figure 4. Old DCs induce enhanced alloimmune responses. a-b, flow-sorted splenic CD11c+ 
DCs from either young or old naïve C57BL/6 mice were used as allogeneic stimulators of young 
DBA/2 splenocytes in ELISpot and proliferation assays either without activation or 
lipopolysaccharide (LPS) activation at low (10ng/ml) and high (100ng/ml) concentrations; (a) 
frequencies of IFNȖ-producing responder splenocytes (n=6/group; *P<0.05; ***P<0.001; 
experiments were performed in triplicates; data are representative of three independent sets of 
experiments) and (b) proliferation rates of responder splenocytes by 3H thymidine incorporation 
(n=6/group; *P<0.05; **P<0.001; experiments performed in triplicates; data are representative 
of three independent sets of experiments) were analyzed. c, Characterization of activation and 
maturation markers (I-Ab/MHC-II, CD40, CD80, and CD86) was performed using mean 
fluorescence intensity (MFI) (n=3/group; *P<0.05; ***P<0.001; grey tinted: young DCs, black 
line: old DCs; representative histogram plots of three independent sets of experiments are 
shown).
 at Universitaet Zuerich on January 7, 2016http://circ.ahajournals.org/Downloaded from 
DOI: 10.1161/CIRCULATIONAHA.114.014917 
24 
Figure 5. IL-17A has a critical role in age-dependent immune responses. a, 7 days after 
transplantation hearts were procured and intragraft levels of IL-17A were analyzed by real-time 
PCR (n=4/group; **, p<0.01; ***, p<0.001). b-c, DCs were isolated from old and young hearts 
(C57BL/6) and co-cultured with naïve CD4+ cells isolated from spleens (DBA/2J) in media 
alone, in Th17-polarizing conditions alone, in presence of lipopolysaccharide (LPS) alone or 
under  Th17 polarizing conditions in presence of LPS. After 7 days, (b) frequencies of CD4+IL-
17A+ cells were assessed by flow cytometry gating on CD4+ cells and (c) cytokine secretion was 
assessed by ELISA (n=3/group; **P<0.01, ***P<0.001 ****P<0.0001). 
Figure 6. Targeting IL-17A in solid organ transplantation abolished donor age-related 
alloimmune responses. a, hearts from old and young C57BL/6 mice were transplanted into 
young DBA/2J recipient mice; recipient mice were treated with 100ȝg of anti-IL-17A or with 
isotype control antibodies (IgG) every other day starting at day 0 and mean survival times (MST) 
were analyzed (n=5/group; *P<0.05; NS=non-significant). b, hearts from old and young 
C57BL/6 mice were transplanted into young BALB/c IL-17A-/- mice and MST was analyzed 
(n=4-5/group; *P<0.05). 
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SUPPLEMENTAL METHODS 
 
Histology, immunohistochemistry and quantification 
At day 7 animals were sacrificed and cardiac allografts were procured. Samples were fixed in 10% 
formalin and embedded in paraffin. Coronary sections were then stained with hematoxylin/eosin 
(Sigma-Aldrich, St. Louis, MO), and analyzed by light microscopy. The degree of rejection was 
determined according to a score system based on the degree of inflammatory infiltration and myocyte 
damage (0=no rejection to 4=severe rejection) according to the International Society of Heart and 
Lung Transplantation (ISHLT) rejection score 11,12. An independent pathologist (R.B.) analyzed all 
sections in a blinded fashion. Immunohistochemistry was performed in paraffin-embedded tissue 
sections with an automated immunostainer (Nexes; Ventana, Tucson, Arizona, USA), applying the 
streptavidin–biotin–peroxidase technique with diaminobenzidine as chromogen. Rat anti-mouse CD4 
mAb (BD Biosciences, San Diego, CA), as well as rat anti-mouse CD8 mAb (BD Biosciences, San 
Diego, CA) were used as primary antibodies. For antigen retrieval heat pretreatment in an autoclave at 
121°C for 5 minutes with citrate buffer (pH 6.0) was performed. Positive cells in 5 randomly selected 
high power fields were counted (HPF; 400 magnification). Data are given as mean ± SEM. An 
independent pathologist analyzed all sections in a blinded fashion. Immunohistochemistry for CD11c+ 
DCs was performed using OCT-embedded, 4µm acetone-fixed mouse tissue sections. Slides were pre-
treated with Peroxidase Block (DAKO USA, Carpinteria, CA) for 5 minutes to quench endogenous 
peroxidase activity. Monoclonal hamster anti-murine CD11c+ (BD Biosciences, San Diego, CA) was 
applied in DAKO diluent at 1:200 for 1 hour. After washing, rabbit anti-rat immunoglobulin antibody 
was applied at 1:750 for 1 hour. Slides were then washed in 50-mM Tris-Cl, pH 7.4 and analyzed with 
anti-rabbit Envision+ kit (DAKO) per manufacturer's instructions. After further washing, 
immunoperoxidase staining was developed using a DAB chromogen (DAKO) prior to counterstaining 
with hematoxylin. 
 
Cell culture, cell proliferation assays 
Isolated naïve CD4+ T cells (0.3x106 cells per well) were co-cultured with isolated CD11c+ DCs 
(0.06x106 cells per well; ratio 5:1) in 48-well flat bottom plates in 0.5ml of complete RPMI 1640 
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media supplemented with 10% FCS, 200mM L-glutamine, 100U/ml penicillin/streptomycin and 5x105 
M 2-mercaptoethanol (RP-10) in presence of 10µg/ml plate-bound anti-mouse α-CD3 (17A2) and 
2µg/ml soluble α-CD28 (37.51). LPS (Sigma-Aldrich) was diluted in PBS and added at a 
concentration of 1µg/ml. Where indicated, cells were cultured in Th17-polarizing conditions (10ng/ml 
of recombinant TGFβ, 100ng/ml of recombinant IL-6, 10mg/ml of anti-IFNγ, and 10mg/ml of anti-
IL4). All recombinant cytokines and antibodies were purchased from eBioscience except recombinant 
TGFβ (R&D Systems, Minneapolis, MN). After 7 days of culture supernatants and cells were 
collected and analyzed by ELISA and flow cytometry, respectively. 
For cell proliferation assays, 0.5×106 splenocytes from transplanted DBA/2J mice were co-cultured 
with irradiated donor-type splenocytes from naïve C57BL/6 mice in 96-well round bottom cell culture 
plates. After 72 hours, cells were pulsed with 3H thymidine (1µCi/ well) and incubated for another 12 
hours. Incorporation of 3H thymidine indicating cell proliferation was then assessed as counts/min, 
using a Wallac Liquid Scintillation Counter (PerkinElmer Inc., Boston, MA, USA).  
To test immunogenic properties of old versus young dendritic cells in vitro, 1×106 splenocytes from 
naïve DBA/2J mice were co-cultured with 104 splenic CD11c+ DCs from young or old naïve B6 mice 
with no LPS-stimulation, with low LPS-stimulation (10ng/ml) or with high LPS-stimulation 
(100ng/ml) in 96-well round bottom cell culture plates and further processed as described above.  
 
Flow Cytometry 
Fluorescence labeled anti-mouse α-CD4 (GK1.5), α-CD8 (53-6.7), α-CD25 (PC61), α-CD11c (HL3), 
α-CD40 (3/23), α-CD44 (IM7), α-CD62L (MEL-14), α-CD80 (16-10A1), α-CD86 (GL1), α-IAb (AF6-
120.1) antibodies were obtained from BD Biosciences (San Jose, CA, USA). Fluorescence labeled 
anti-mouse α-Foxp3 (150D/E4), α-IFNγ (XMG1.2) and α-IL-17A (eBio17B7) were purchased from 
eBioscience (San Diego, CA, USA). For compensation and gate setting, permeabilized and 
unpermeabilized unstained cells were used. Intracellular staining for Foxp3, IFNγ and IL-17A was 
performed according to manufacturer’s protocols. Cells were re-stimulated in complete media (RPMI 
media containing 10% FCS, 1% L-Glutamine, 1% Penicillin/Streptomycin; all Bio Whittaker, 
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Walkersville, MD) for 4 hours at 37°C with ionomycin, phorbol 12-myristate 13-acetate and 
Brefelding A (eBioscience). Cells were fixed and permeabilized using Cytofix/Cytoperm solution (BD 
Biosciences). Flow cytometry measurements were performed using a FACSCalibur system (BD), and 
data were analyzed using FlowJo (Tree Star, Ashland, OR, USA).  
 
RNA extraction and real-time PCR  
RNA extraction from cardiac allografts was performed using RNAqueous extraction kit according to 
the manufacturer’s protocol (Applied Biosystems, Carlsbad, CA, USA). Briefly, 1 mg of heart tissue 
was homogenized in lysis buffer (total volume of 0.5 ml) and passed through a column. After 
successive washes, RNA was eluted and reverse transcription was performed using i-Script® cDNA 
synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA). For real-time PCR reactions IL-17A 
(MM5419) measurements were performed with Taqman primers and probes from Applied Biosystems. 
Relative gene expression was determined using the housekeeping gene GAPDH (MM99999915_g1) 
as control.  
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SUPPLEMENTAL FIGURES AND LEGENDS 
 
Supplemental Figure 1. Older cardiac allografts elicit more potent systemic alloimmune 
responses. Hearts from old and young C57BL/6 mice were transplanted into young DBA/2J mice; 7 
days after transplantation, mice were euthanized and splenocytes were analyzed by flow cytometry for 
a, frequencies of CD4+CD25+FoxP3+ Tregs and CD4+/CD8+ effector cells (CD44high CD62Llow) 
(n=4/group; *P<0.05) and b, frequencies of CD4+IFNγ+ and CD8+IFNγ+ T cells (n=4/group; *P<0.05). 
c-d, Splenocytes from young DBA/2J mice were co-cultured with irradiated donor-type splenocytes 
from old or young C57BL/6 mice and (c), frequencies of splenocytes producing IL-6 and IFNγ and (d) 
proliferation rates were analyzed by ELISpot and 3H-thymidine incorporation, respectively 
(n=4/group; **P<0.01; ***P<0.001; data are representative of three independent sets of experiments).   
c 
a 
b 
d 
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Supplemental Figure 2. Systemic immune responses were comparable after the transplantation 
of chimeric young and old hearts. 24 hours after irradiation, bone marrow transplantation from 
young syngeneic C57BL/6 mice was performed to reconstitute passenger leukocytes within donor 
hearts. 7 days after transplantation, mice were euthanized and splenocytes were analyzed by flow 
cytometry for a, frequencies of CD4+CD25+Foxp3+ Tregs and CD4+/CD8+ effector T cells (CD44high 
CD62Llow) (n=4/group; NS, non-significant). b-c, Splenocytes from young DBA/2J mice were co-
cultured with splenocytes from old or young chimeric C57BL/6 mice and (b) frequencies of 
splenocytes producing IL-6 and IFNγ and (c) proliferation rates were analyzed by ELISpot and 3H-
thymidine incorporation, respectively (n=4/group; **P<0.01; data are representative of three 
independent sets of experiments).   
b 
a 
c 
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Supplemental Figure 3. Systemic alloimmune responses to grafts procured from donors 
pretreated with clodronate were age-independent. DC-depleted hearts from old and young 
C57BL/6 mice were transplanted into young DBA/2J mice; 7 days after transplantation, mice were 
euthanized and splenocytes were analyzed by flow cytometry for (a) frequencies of 
CD4+CD25+FoxP3+ Tregs and CD4+/CD8+ effector T cells (CD44high CD62Llow) (n=4/group; NS, non-
significant) and (b) for frequencies of CD4+IFNγ+ and CD8+IFNγ+ T cells (n=4/group; NS, non-
significant). c-d, Splenocytes from young DBA/2J mice where co-cultured with splenocytes from DC-
depleted old or young C57BL/6 mice and (c), frequencies of splenocytes producing IL-6 and IFNγ and 
(d) proliferation rates were analyzed by ELISpot and 3H-thymidine incorporation, respectively 
(n=4/group; NS, non-significant, data are representative of three independent sets of experiments).  
 
c 
a 
b 
d 
